TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26529073
Drug: Tdap (tetanus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap (tetanus, diphtheria acellular pertussis) vaccine
Study: 26529073
Drug: Tetanus only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus only vaccine (Control)
Study: 12757067
Drug: Morphine 0.3
Normalized name: ethylmorphine 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.3 mg in normal saline 0.3 ml
Study: 12757067
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.3 ml
Study: 8883232
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg dolasetron mesilate
Study: 8883232
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg dolasetron mesilate
Study: 8883232
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg dolasetron mesilate
Study: 8883232
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate (all doses pooled)
Study: 1589561
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of sCT
Study: 28385659
Drug: Semaglutide 0.5
Normalized name: semaglutide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.5 mg once weekly
Study: 28385659
Drug: Semaglutide 1.0
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1.0 mg once weekly
Study: 19730273
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for suicide prevention (CBT-SP)
Study: 15318465
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 2.5 microg kg(‐1) during induction (Groups 2 and 4)
Study: 15318465
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution during induction (Groups 1 and 3)
Study: 3602017
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bendroflumethiazide plus 15 mmol potassium chloride
Study: 27421987
Drug: functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: functionally orientated treatment (SDA)
Study: 27421987
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant treatment
Study: 20843224
Drug: 0.2 µg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 µg/kg/hr
Study: 20843224
Drug: 0.4 µg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 µg/kg/hr
Study: 12617332
Drug: Isovolemic phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isovolemic phase with sequential ultra‐filtration (ISO GROUP)
Study: 7491878
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (17.85 mmol (714 mg)/d)
Study: 6267617
Drug: Pivmecillinam/pivampicillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam/pivampicillin (200 mg pivmecillinam and 250 mg pivampicillin, twice daily for 10 days)
Study: 6267617
Drug: Co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim, twice daily for 10 days)
Study: 27505611
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dried ginger capsules twice daily
Study: 8595643
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg once daily (titrated to 10 mg after 4 weeks)
Study: 2914082
Drug: Potassium (KCl;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium (KCl; 20 mEq three times daily)
Study: 2914082
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (Ca; 500 mg twice daily)
Study: 30582240
Drug: Cisplatin, fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy
Study: 25487930
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.05-0.1 µg·kg‐1·min‐1)
Study: 19484483
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) every 28 days with high-dose radiotherapy
Study: 19484483
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) every 28 days with reduced-dose radiotherapy
Study: 18728281
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors or ARBs initiated during the study
Study: 12072043
Drug: Oestrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen supplementation (oestradiol valerate 1 mg daily, n = 7)
Study: 29775119
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy and diabetic diet regime
Study: 25208464
Drug: Benralizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (100 mg subcutaneously every 4 weeks for three doses, then every 8 weeks for five doses over 48 weeks)
Study: 19354088
Drug: Atropine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (2.0 mg intramuscularly) at rest (T1)
Study: 11356434
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg, increased to a maximum of 25 mg twice daily
Study: 7802299
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at incremental rates (30, 60, and 120 micrograms.kg‐1.min‐1)
Study: 466336
Drug: Gutter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gutter treatment for ingrowing toenails
Study: 28992899
Drug: Online cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioral therapy (CBT) plus three therapist support calls
Study: 28992899
Drug: Online cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioral therapy (CBT) without therapist support calls
Study: 25882864
Drug: Natriuretic peptide
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuretic peptide receptor type C mRNA expression
Study: 25882864
Drug: Natriuretic peptide
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuretic peptide receptor type A mRNA expression
Study: 24062325
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical care (CC)
Study: 20864417
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (90-minute infusion)
Study: 19407805
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at bedtime (100 mg/day)
Study: 19407805
Drug: Aspirin on
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin on awakening (100 mg/day)
Study: 15128894
Drug: Concomitant cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant cisplatin (100 mg/m² on days 1, 22, and 43) with radiotherapy (66 Gy over 6.5 weeks)
Study: 11922401
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg, 20 mg, 30 mg
Study: 8104017
Drug: Triprolidine 10
Normalized name: phenylephrine HCl/triprolidine 10 mg-2.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 10 mg
Study: 320827
Drug: Lofepramine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine (70 mg t.i.d.)
Study: 320827
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg t.i.d.)
Study: 19335936
Drug: Intravenous synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous synthetic THC (2.5 mg)
Study: 16750125
Drug: One drug
Normalized name: mometasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drug taken at bedtime
Study: 16750125
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs taken in the morning
Study: 15280529
Drug: Pre-emptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive treatment (angioplasty and/or open surgery)
Study: 11315820
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in premeal insulin dose
Study: 9134643
Drug: High-intensity coumarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity coumarin therapy
Study: 9134643
Drug: Low-intensity coumarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity coumarin therapy
Study: 15472191
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg/d
Study: 8185424
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 1.25 mg/d
Study: 26291918
Drug: 0.50% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% DHEA (prasterone) ovules administered intravaginally daily for 12 weeks
Study: 23599120
Drug: 3 to
Normalized name: Melquin-3 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 12 mg kg(‐1) per day of iron supplementation based on the ZnPP/H
Study: 23599120
Drug: 2.2 mg
Normalized name: menthol 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 mg kg(‐1) per day of ferrous sulfate (control)
Study: 21883322
Drug: AST-120 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 2 g tds
Study: 8230988
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) administered intravenously (dose 100 m/kg b.w.)
Study: 7380201
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme therapy
Study: 3633631
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pancreatic enzyme therapy)
Study: 31682878
Drug: SM-VAP patients
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-VAP patients receiving early adequate therapy (n=70, 68.6%)
Study: 31682878
Drug: Adequate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate treatment (monotherapy or combination of antimicrobials)
Study: 26803589
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (carbohydrate <40 g/day)
Study: 20051257
Drug: Wujijing Oral
Normalized name: influenza B virus B/Hubei Wujigang/158/2009/antigen
DrugBank: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated) (DB10780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wujijing Oral Liquid (WJJ) 10mL twice daily for 2 menstrual cycles
Study: 18038179
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser therapy (810 nm)
Study: 18038179
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy
Study: 12759802
Drug: All antipsychotic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antipsychotic medications
Study: 10553856
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg succinylcholine
Study: 8688343
Drug: Active pastilles
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pastilles containing amphotericin, polymyxin and tobramycin, suck four times daily
Study: 25864623
Drug: Marine omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine omega-3 fatty acids (Omacor(®) fish oil, 1 g/d)
Study: 21987240
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg
Study: 21987240
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin 400 mg
Study: 15905296
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus flutamide (62.5 mg/day)
Study: 15905296
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (OC) monotherapy
Study: 15905296
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception plus flutamide-metformin
Study: 12569142
Drug: 9-cis-retinoic acid
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-cis-retinoic acid (100 mg daily for 3 months)
Study: 12569142
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (1 mg/kg) + alpha-tocopherol (1200 IU) for 3 months
Study: 1759096
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tincture of belladonna (0.01 mg/kg weight of atropine)
Study: 1759096
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup containing no belladonna
Study: 31773209
Drug: Cherry flavored
Normalized name: Syrspend SF Cherry Flavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherry flavored e-liquid (24 mg/ml)
Study: 31773209
Drug: Vanilla flavored
Normalized name: OCTINOXATE 3.6 g in 1 g / OCTISALATE 2.5 g in 1 g / OXYBENZONE 1.5 g in 1 g TOPICAL LIPSTICK [Lip Balm Vanilla Flavored]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanilla flavored e-liquid (24 mg/ml)
Study: 31773209
Drug: Menthol flavored
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol flavored e-liquid (24 mg/ml)
Study: 30684522
Drug: Hydrocortisone (unspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (unspecific MR/GR agonist)
Study: 30684522
Drug: Fludrocortisone (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (specific MR agonist)
Study: 28760368
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACG)
Study: 28760368
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy (NACG)
Study: 19919718
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (bathing, dressing, eating, walking) without counselling from a physical therapist
Study: 11139961
Drug: sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (160 mg bid)
Study: 9052343
Drug: Propafenone 2
Normalized name: propafenone 225 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 2 mg/kg over 30 minutes, followed by oral propafenone 150 mg 3 times daily
Study: 9052343
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg 3 times daily
Study: 2427858
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol for 3 weeks, then increased to 300 mg or added diuretic for another 3 weeks
Study: 2427858
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg celiprolol
Study: 2427858
Drug: Diuretic added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic added to treatment
Study: 2427858
Drug: Celiprolol administered
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol administered for up to 6 weeks
Study: 31606288
Drug: Mid-treatment MRI
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-treatment MRI showing complete response (mCR)
Study: 31606288
Drug: Mid-treatment MRI
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-treatment MRI showing partial response (mPR)
Study: 20392890
Drug: Red tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red tomato paste (200 g/d providing 16 mg lycopene)
Study: 20392890
Drug: Purified lycopene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified lycopene (16 mg/d)
Study: 20392890
Drug: Yellow tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow tomato paste (200 g/d providing 0 mg lycopene)
Study: 18923312
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intrathecal morphine (M-group)
Study: 12808527
Drug: Group-based multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based multidisciplinary cognitive behavioral therapy
Study: 12808527
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy cognitive behavioral therapy
Study: 11304027
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg per min for 20 min)
Study: 11304027
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) infusion
Study: 1365868
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 supplementation (20 mg pyridoxine HCL daily for 3 months)
Study: 6532126
Drug: Indomethacin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (4 X 25 mg, orally)
Study: 6532126
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (4 X 250 mg, orally)
Study: 6532126
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg) plus sodium salicylate (250 mg) (Pelsonin, 4 X 1 capsules)
Study: 30439945
Drug: WHO dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO dose pole for praziquantel (PZQ) dosing
Study: 30439945
Drug: Modified dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dose pole for praziquantel (PZQ) dosing
Study: 25643511
Drug: 2-week anti-HP
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week anti-HP therapy plus 90-day oral iron
Study: 25643511
Drug: 2-week anti-HP
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week anti-HP therapy alone
Study: 25643511
Drug: 90-day oral
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-day oral iron alone
Study: 8607674
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Duraflo II)
Study: 1833245
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg/d
Study: 7139067
Drug: S-carboxymethylcysteine in
Normalized name: S-carboxymethylcysteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine in hard gelatin capsule
Study: 7139067
Drug: S-carboxymethylcysteine syrup
Normalized name: S-carboxymethylcysteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine syrup
Study: 30088162
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen plus thoracic epidural analgesia (TEA)
Study: 19129989
Drug: Acetaminophen 15
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 15 mg/kg/dose (n=112)
Study: 19129989
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg/kg/dose (n=105)
Study: 19129989
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg/dose (n=84)
Study: 15385923
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) given as adjunct to chemotherapy (ATRA-arm, n=122)
Study: 15385923
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy (n=31)
Study: 11125238
Drug: Tacrine 40
Normalized name: tacrine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine 40 mg
Study: 11806464
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 or 8 mg once daily)
Study: 11806464
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 or 40 mg once daily)
Study: 7822984
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (200 mg of oral vitamin E for 4-8 weeks)
Study: 38214
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg labetalol
Study: 29248384
Drug: Telmisartan/Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine + Hydrochlorothiazide (TAH) 40/5 mg + 12.5 mg
Study: 29248384
Drug: Telmisartan/Amlodipine (TA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine (TA) 40/5 mg
Study: 18769354
Drug: EVG/r alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVG/r alone (200/100 mg once daily)
Study: 18769354
Drug: EVG added
Normalized name: EVG
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EVG added to TPV/r (500/200 mg twice daily)
Study: 18769354
Drug: EVG added
Normalized name: EVG
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EVG added to DRV/r (600/100 mg twice daily)
Study: 18769354
Drug: EVG/r (200/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVG/r (200/100 mg once daily)